Monomethyl fumarate

Generic Name: Monomethyl fumarate

Brand Names: Bafiertam

Drug Type: Small Molecule

Chemical Formula: C_₅H_₆O_₄

CAS Number: 2756-87-8

Unique Ingredient Identifier: 45IUB1PX8R

Associated Conditions: -

Associated Therapies: -

Clinical Trials

ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis

Phase 4

Conditions: Hematopoietic Stem Cell Transplantation

Interventions: Drug: ATG
Drug: CsA
Drug: MTX
Drug: MMF

First Posted Date: 2019-12-18

Last Posted Date: 2019-12-18

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 266

Registration Number: NCT04203108

Locations: 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China

Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Bafiertam
Drug: Tecfidera

First Posted Date: 2019-07-17

Last Posted Date: 2020-01-18

Lead Sponsor: Banner Life Sciences LLC

Target Recruit Count: 210

Registration Number: NCT04022473

Locations: 🇺🇸
BioPharma Services, Inc., Columbia, Missouri, United States

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Phase 2

Recruiting

Conditions: Systemic Sclerosis

Interventions: Other: Placebo Subcutaneous Injection
Drug: Belimumab
Other: Placebo Infusion
Drug: Rituximab
Drug: MMF

First Posted Date: 2019-02-18

Last Posted Date: 2024-03-01

Lead Sponsor: Hospital for Special Surgery, New York

Target Recruit Count: 30

Registration Number: NCT03844061

Locations: 🇺🇸
Hospital for Special Surgery, New York, New York, United States

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165
Drug: MMF

First Posted Date: 2018-09-06

Last Posted Date: 2018-12-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 131

Registration Number: NCT03660436

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

REduCing Immunogenicity to PegloticasE (RECIPE) Study

Phase 2

Completed

Conditions: Gout Chronic

Interventions: Drug: Placebo
Drug: Pegloticase 8 MG/ML [Krystexxa]
Drug: MMF

First Posted Date: 2017-10-06

Last Posted Date: 2022-03-16

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 35

Registration Number: NCT03303989

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis

Phase 3

Completed

Conditions: Takayasu Arteritis

Interventions: Drug: MMF
Drug: CYC
Drug: Glucocorticoids
Drug: MTX
Drug: AZA

First Posted Date: 2017-03-30

Last Posted Date: 2023-08-30

Lead Sponsor: Chinese SLE Treatment And Research Group

Target Recruit Count: 138

Registration Number: NCT03096275

Locations: 🇨🇳
General Hospital of Tianjing Medical University, Tianjin, China
🇨🇳
Hebei Provincial Hospital, Shijiazhuang, Hebei, China
🇨🇳
Peking Union Medical College Hospital, Beijing, China

and more 4 locations

Natural Killer Cells Reconstitution Kinetics Post Haploidentical Transplantation

Conditions: Natural Killer Cell Mediated Immunity

Interventions: Drug: MMF

First Posted Date: 2016-11-30

Last Posted Date: 2020-10-05

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 200

Registration Number: NCT02978274

Locations: 🇨🇳
Peking University Institute of Hematology, Beijing, Beijing, China

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Phase 2

Active, not recruiting

Conditions: Myelodysplastic Syndrome
Multiple Myeloma
Lymphoplasmacytic Lymphoma
Marginal Zone B-cell Lymphoma
Prolymphocytic Leukemia
MRD Positive Leukemia
Relapsed T-Cell Lymphoma
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia/Lymphoma
Burkitt's Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: MMF
Drug: Sirolimus
Radiation: TBI
Biological: Umbilical cord blood cell infusion
Biological: ATG

First Posted Date: 2016-03-30

Last Posted Date: 2023-02-24

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 16

Registration Number: NCT02722668

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Allo HSCT Using RIC for Hematological Diseases

Phase 2

Completed

Conditions: Chronic Myelogenous Leukemia
Lymphoplasmacytic Lymphoma
Mantle-Cell Lymphoma
Lymphoblastic Lymphoma
Acute Myelogenous Leukemia
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Burkitt's Lymphoma
Hematological Diseases
B-Cell Lymphoma

Interventions: Drug: Allopurinol
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: ATG
Radiation: TBI
Drug: Tacrolimus
Drug: MMF
Biological: Peripheral Blood Stem Cells
Biological: Related or Unrelated Bone Marrow Cells

First Posted Date: 2016-01-21

Last Posted Date: 2023-09-21

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 156

Registration Number: NCT02661035

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome

Phase 3

Terminated

Conditions: Frequent Relapsing Nephrotic Syndrome
Steroid Dependent Nephrotic Syndrome

Interventions: Drug: Rituximab
Drug: MMF

First Posted Date: 2015-03-17

Last Posted Date: 2019-03-26

Lead Sponsor: Nationwide Children's Hospital

Target Recruit Count: 3

Registration Number: NCT02390362

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy